Inhibition of hepatitis B virus production by Boehmeria nivea root extract in HepG2 2.2.15 cells

World Journal of Gastroenterology

Volumn 12, Issue 35, 2006, Pages 5721-5725

  Huang, Kai Ling ^a   Lai, Yiu Kay ^a,b   Lin, Chih Chien ^a   Chang, Jia Ming ^c  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b DA YEH UNIVERSITY   (Taiwan)

^c DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

Author keywords

Anti hepatitis B virus; Antiviral agent; Boehmeria nivea; Hepatitis B virus; HepG2 2.2.15; Medicinal herb

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS E ANTIGEN; NUCLEOSIDE DERIVATIVE; PLANT EXTRACT; RAMIE EXTRACT; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA DETERMINATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; NORTHERN BLOTTING; PLANT ROOT; PROTEIN EXPRESSION; RAMIE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SOUTHERN BLOTTING; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 33750126154     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i35.5721     Document Type: Article

References (31)

1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129
2. Knipe DM, Howley PM. Fundamental virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001
3. Summers J, Mason WS. Replication of the genome of a hepatitis B - like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-415
4. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831-1838
5. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198-1209
6. Buster EH, Janssen HL. Antiviral treatment for chronic hepatitis B virus infection - immune modulation or viral suppression? Neth J Med 2006; 64: 175-185
7. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003; 39 Suppl 1: S93-98
8. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427
9. Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001; 4: 118-128
10. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297
11. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-290
12. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-3507
13. Gesler WM. Therapeutic landscapes: medical issues in light of the new cultural geography. Soc Sci Med 1992; 34: 735-746
14. Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med 2004; 116: 478-485
15. Coon JT, Ernst E. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. J Hepatol 2004; 40: 491-500
16. Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 2002; 97: 2391-2397
17. Chen HC, Chou CK, Kuo YH, Yeh SF. Identification of a protein kinase C (PKC) activator, daphnoretin, that suppresses hepatitis B virus gene expression in human hepatoma cells. Biochem Pharmacol 1996; 52: 1025-1032
18. Chen HC, Chou CK, Lee SD, Wang JC, Yeh SF. Active compounds from Saussurea lappa Clarks that suppress hepatitis B virus surface antigen gene expression in human hepatoma cells. Antiviral Res 1995; 27: 99-109
19. Huang RL, Chen CC, Huang YL, Hsieh DJ, Hu CP, Chen CF, Chang C. Osthole increases glycosylation of hepatitis B surface antigen and suppresses the secretion of hepatitis B virus in vitro. Hepatology 1996; 24: 508-515
20. Liu J, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepat 2001; 8: 358-366
21. Lin CC, Yen MH, Lo TS, Lin JM. Evaluation of the hepatoprotective and antioxidant activity of Boehmeria nivea var. nivea and B. nivea var. tenacissima. J Ethnopharmacol 1998; 60: 9-17
22. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84: 1005-1009
23. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 1987; 47: 943-946
24. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495-8499
25. Lu X, Hazboun T, Block T. Limited proteolysis induces woodchuck hepatitis virus infectivity for human HepG2 cells. Virus Res 2001; 73: 27-40
26. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661
27. Dixon JS, Boehme RE. Lamivudine for the treatment of chronic hepatitis B. Acta Gastroenterol Belg 2000; 63: 348-356
28. Weber O, Schlemmer KH, Hartmann E, Hagelschuer I, Paessens A, Graef E, Deres K, Goldmann S, Niewoehner U, Stoltefuss J, Haebich D, Ruebsamen-Waigmann H, Wohlfeil S. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res 2002; 54: 69-78
29. Zlotnick A, Ceres P, Singh S, Johnson JM. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J Virol 2002; 76; 4848-4854
30. Lu X, Tran T, Simsek E, Block TM. The alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture. J Virol 2003; 77: 11933-11940
31. Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D, Rubsamen-Waigmann H. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299: 893-896